JG
CHRS icon

Jefferies Group’s Coherus Oncology CHRS Stock Holding History

Jefferies Group’s Portfolio CHRS Stock Details CHRS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-19,128
Closed -$305K – 1572
2021
Q4 		$305K Buy
+19,128
New +$335K ﹤0.01% 1294
2021
Q3 		– Sell
-110,285
Closed -$1.53M – 1741
2021
Q2 		$1.53M Buy
+110,285
New +$1.56M 0.01% 844
2020
Q2 		– Sell
-41,091
Closed -$666K – 1393
2020
Q1 		$666K Buy
41,091
+17,366
+73% +$321K 0.01% 1204
2019
Q4 		$427K Sell
23,725
-6,275
-21% -$116K ﹤0.01% 1911
2019
Q3 		$608K Buy
30,000
+10,000
+50% +$200K ﹤0.01% 1775
2019
Q2 		$442K Buy
+20,000
New +$347K ﹤0.01% 1725
2019
Q1 		– Sell
-10,060
Closed -$91K – 2343
2018
Q4 		$91K Buy
+10,060
New +$116K ﹤0.01% 1970
2017
Q3 		– Sell
-26,218
Closed -$376K – 2358
2017
Q2 		$376K Buy
26,218
+11,992
+84% +$231K ﹤0.01% 1745
2017
Q1 		$301K Buy
+14,226
New +$350K ﹤0.01% 1828
2016
Q4 		– Sell
-3,954
Closed -$106K – 2227
2016
Q3 		$106K Sell
3,954
-9,697
-71% -$265K ﹤0.01% 2029
2016
Q2 		$231K Buy
+13,651
New +$256K ﹤0.01% 1761

Other funds holding CHRS

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Temasek Holdings
Temasek Holdings Singapore $30.5B AUM 13.98% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
KKRC
Kohlberg Kravis Roberts & Co New York $5.35B AUM 63.01% 1-Year Est. Return
ACB
Aristotle Capital Boston Boston, Massachusetts $1.61B AUM 19.82% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

Jefferies Group's CHRS Position: Q1 2022 in Review

Jefferies Group sold out of Coherus Oncology (CHRS) in Q1 2022, closing a stake of 19,128 shares — an estimated $305K sold.

Jefferies Group first reported a position in CHRS in Q2 2016 and held it in 11 quarters. The position peaked at $1.53M in Q2 2021. 183 funds tracked by Wall St. Rank hold CHRS as of Q1 2022.

  • Jefferies Group reported no remaining Coherus Oncology position as of Q1 2022 after selling out during the quarter.
  • Jefferies Group sold 19,128 Coherus Oncology shares in Q1 2022, an estimated $305K.
  • Jefferies Group first reported a position in Coherus Oncology in Q2 2016 and held it in 11 quarters.
  • Jefferies Group's Coherus Oncology position peaked at $1.53M in Q2 2021.
  • 183 funds tracked by Wall St. Rank held Coherus Oncology as of Q1 2022.

Based on Jefferies Group's 13F filing for Q1 2022, filed 16 May 2022.